CASSAVA SCIENCES INC

For the period ended Dec 31, 2023. Filed Feb 28, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 28, 2024

FLNA$0.49+8.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(In thousands, except share and par value data)

	December 31,
	2023	2022
ASSETS
Current assets:
Cash and cash equivalents	$121,136	$201,015
Prepaid expenses and other current assets	8,497	10,211
Total current assets	129,633	211,226
Operating lease right-of-use assets	—	122
Property and equipment, net	21,854	22,864
Intangible assets, net	176	622
Total assets	$151,663	$234,834
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and other accrued expenses	$10,573	$4,017
Accrued development expense	3,037	2,280
Accrued compensation and benefits	200	170
Operating lease liabilities, current	—	104
Other current liabilities	385	492
Total current liabilities	14,195	7,063
Operating lease liabilities, non-current	—	35
Other non-current liabilities	—	197
Total liabilities	14,195	7,295
Commitments and contingencies (Notes 10, 11 and 12)
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding	—	—
Common stock, $0.001 par value; 120,000,000 shares authorized; 42,236,919 and 41,735,557 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	42	42
Additional paid-in capital	518,195	511,049
Accumulated deficit	(380,769)	(283,552)
Total stockholders' equity	137,468	227,539
Total liabilities and stockholders' equity	$151,663	$234,834

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.